A. Feeney

发表

Adjuvant chemoradiotherapy versus radiotherapy alone for women with high-risk endometrial cancer (PORTEC-3): final results of an international, open-label, multicentre, randomised, phase 3 trial

H. Putter, C. Haie-meder, H. Kitchener, 2018, The Lancet. Oncology.

An international, phase III randomized trial in patients with mucinous epithelial ovarian cancer (mEOC/GOG 0241) with long-term follow-up: and experience of conducting a clinical trial in a rare gynecological tumor

M. Gore, J. Ledermann, G. Rustin, 2019, Gynecologic oncology.

STATEC: A randomised trial of non-selective versus selective adjuvant therapy in high risk apparent stage 1 endometrial cancer.

H. Kitchener, J. Ledermann, T. Mould, 2018 .

OV21/PETROC: A randomized Gynecologic Cancer Intergroup (GCIG) phase II study of intraperitoneal (IP) versus intravenous (IV) chemotherapy following neoadjuvant chemotherapy and optimal debulking surgery in epithelial ovarian cancer (EOC).

H. Mackay, E. Eisenhauer, D. Provencher, 2016 .

A randomised, placebo-controlled trial of weekly paclitaxel and saracatinib (AZD0530) in platinum-resistant ovarian, fallopian tube or primary peritoneal cancer†.

H. Earl, J. Ledermann, G. Hall, 2014, Annals of oncology : official journal of the European Society for Medical Oncology.

Measure of Ovarian Symptoms and Treatment concerns (MOST) indexes and their associations with health-related quality of life in recurrent ovarian cancer.

M. Stockler, A. Oza, A. Okamoto, 2022, Gynecologic oncology.

Long-term toxicity and health-related quality of life after adjuvant chemoradiotherapy or radiotherapy alone for high-risk endometrial cancer in the randomised PORTEC-3 trial.

H. Putter, C. Haie-meder, H. Kitchener, 2020, International journal of radiation oncology, biology, physics.

ICON 9—an international phase III randomized study to evaluate the efficacy of maintenance therapy with olaparib and cediranib or olaparib alone in patients with relapsed platinum-sensitive ovarian cancer following a response to platinum-based chemotherapy

J. Ledermann, G. Jayson, L. Mileshkin, 2020, International Journal of Gynecological Cancer.

Symptom burden and quality of life with chemotherapy for recurrent ovarian cancer: the Gynecologic Cancer InterGroup-Symptom Benefit Study

M. Stockler, A. Oza, A. Okamoto, 2022, International Journal of Gynecological Cancer.

Reducing Uncertainty: Predictors of Stopping Chemotherapy Early and Shortened Survival Time in Platinum Resistant/Refractory Ovarian Cancer-The GCIG Symptom Benefit Study.

M. Stockler, A. Oza, A. Okamoto, 2017, The Oncologist.

Measuring what matters MOST: validation of the Measure of Ovarian Symptoms and Treatment, a patient-reported outcome measure of symptom burden and impact of chemotherapy in recurrent ovarian cancer

M. Stockler, A. Oza, A. Okamoto, 2017, Quality of Life Research.

Adjuvant chemoradiotherapy versus radiotherapy alone in women with high-risk endometrial cancer (PORTEC-3): patterns of recurrence and post-hoc survival analysis of a randomised phase 3 trial

H. Putter, C. Haie-meder, H. Kitchener, 2019, The Lancet. Oncology.

A phase II randomised, placebo-controlled trial of low dose (metronomic) cyclophosphamide and nintedanib (BIBF1120) in advanced ovarian, fallopian tube or primary peritoneal cancer.

J. Ledermann, R. Glasspool, G. Rustin, 2020, Gynecologic oncology.

A phase II study of weekly neoadjuvant chemotherapy followed by radical chemoradiation for locally advanced cervical cancer

J. Ledermann, A. Hackshaw, M. Hall-Craggs, 2013, British Journal of Cancer.

OC-0369: Long-Term Quality of Life after (chemo)radiotherapy for high-risk Endometrial Cancer in PORTEC-3

H. Putter, D. Katsaros, J. Ledermann, 2020 .

Socioeconomic and sex differentials in reason for sickness absence from the Whitehall II Study.

M. Marmot, F. North, J. Head, 1998, Occupational and environmental medicine.

Sickness absence in the Whitehall II study, London: the role of social support and material problems.

M. Marmot, S. Stansfeld, J. Head, 1995, Journal of epidemiology and community health.

A randomized placebo-controlled trial of saracatinib (AZD0530) plus weekly paclitaxel in platinum-resistant ovarian, fallopian-tube, or primary peritoneal cancer (SaPPrOC)

H. Earl, J. Ledermann, G. Hall, 2013 .